-- Revenue increased 33% to $255.6 million; Product Sales increased 32%
ALISO VIEJO, Calif. Aug. 2 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced second quarter financial results for 2010.
“The team at Valeant accomplished a great deal this quarter, both operationally and strategically,” stated J. Michael Pearson, chairman and chief executive officer. “We completed five acquisitions in the quarter and grew our top and bottom line over 30% over 2009. We also embarked upon an exciting new strategic opportunity with our announcement of the proposed merger between Biovail and Valeant, which we hope to complete before the end of the year. These activities continue the transformation of Valeant into a diversified, specialty pharmaceutical company focused on growth and cash flow generation.”
Revenues
Total revenue was $255.6 million in the second quarter of 2010 as compared to $191.7 million in the second quarter of 2009, an increase of 33%.
Product sales in the Specialty Pharmaceuticals segment were $126.9 million in the second quarter of 2010, as compared to $96.6 million in the second quarter of 2009, an increase of 31%. At constant exchange rates, Specialty Pharmaceuticals product sales increased 27%. Within the Specialty Pharmaceuticals segment, alliance and service revenue was $30.1 million in the second quarter of 2010 as compared to $12.2 million in the year-ago quarter, which included an $11.2 million profit share related to the 1% clindamycin and 5% benzoyl peroxide product (IDP-111) that was launched by Mylan in August 2009.
Product sales in Branded Generics - Latin America were $51.8 million in the second quarter of 2010 as compared to $36.2 million in the same period in 2009, an increase of 43%. At constant exchange rates, product sales in Latin America increased 33%.
Product sales in Branded Generics - Europe were $40.8 million in the second quarter of 2010 as compared to $34.0 million in the same period in 2009, an increase of 20%. At constant exchange rates, product sales in Europe increased 17%.
Ribavirin royalties were $6.0 million in the second quarter of 2010 as compared to $12.6 million in the second quarter of 2009, a decrease of 53%. This expected decrease is primarily attributable to the expiration of royalty terms in most European countries.
Organic Growth
Organic growth for total product sales in the second quarter of 2010 was 6% as compared to the second quarter of 2009. This included the Specialty Pharmaceutical organic growth rate of 7%; Branded Generics - Latin America organic growth rate of 1% and Branded Generics - Europe organic growth rate of 9%. Organic growth for the first six months of 2010 was 9% as compared to the first six months of 2009. This included the Specialty Pharmaceutical organic growth rate of 15%; Branded Generics - Latin America organic growth rate of 2% and Branded Generics - Europe organic growth rate of 0%.
Income and Cash Flow
Income from continuing operations was $32.2 million for the second quarter of 2010, or $0.39 per diluted share, as compared to $33.0 million, or $0.39 per diluted share, for the second quarter of 2009. On an adjusted non-GAAP (Cash) EPS basis, adjusted income from continuing operations was $57.1 million, or $0.69 per diluted share, in the second quarter of 2010 as compared to adjusted income from continuing operations of $43.2 million, or $0.52 per diluted share, in the second quarter of 2009, an increase of 33%.
GAAP cash flow from operations, which includes acquisition transaction fees, for the second quarter of 2010 was $59.9 million as compared to $44.5 million for the second quarter of 2009. Adjusted non-GAAP cash flow from operations for the second quarter of 2010 was $61.7 million as compared to $55.0 million for the second quarter of 2009.
Merger With Biovail Corporation
On June 20, 2010, Valeant and Biovail entered into a definitive merger agreement providing for a business combination whereby Valeant will merge with a wholly owned subsidiary of Biovail and the name of the combined company will be changed to Valeant Pharmaceuticals International, Inc. Valeant and Biovail currently expect to complete the merger before the end of 2010, subject to the receipt of required shareholder and regulatory approvals and the satisfaction or waiver of the financing and other conditions to the merger described in the merger agreement. On July 22, 2010, the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the proposed merger.
2010 Guidance
The company is updating its previous adjusted non-GAAP (Cash) EPS target and is now targeting adjusted non-GAAP (cash) EPS between $2.80 - $3.05 in 2010, up from prior guidance of $2.65 to $2.90. This guidance does not assume the completion of any business-development transactions not completed as of August 2, 2010 and excludes the potential effect of certain costs incurred and expected to be incurred in connection with the pending Biovail merger.
Conference Call and Webcast Information
Valeant will host a conference call and a live Internet webcast along with a slide presentation today at 10:00 a.m. EDT (7:00 a.m. PDT) to discuss its second quarter financial results for 2010. The dial-in number to participate on this call is (877) 295-5743, confirmation code 87267374. International callers should dial (973) 200-3961, confirmation code 87267374. A replay will be available approximately two hours following the conclusion of the conference call through August 9, 2010 and can be accessed by dialing (800) 642-1687, or (706) 645-9291, confirmation code 87267374. The live webcast of the conference call may be accessed through the investor relations section of Valeant’s corporate Web site at www.valeant.com.
About Valeant
Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.
Forward-looking Statements
This press release may contain forward-looking statements, including, but not limited to, statements regarding our performance and growth in 2010 and guidance with respect to expected adjusted non-GAAP (cash) earnings per share, the transformation of Valeant, and the expected timing and consummation of the proposed merger with Biovail. Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission (“SEC”) and risks and uncertainties relating to the proposed merger, as detailed from time to time in Valeant’s and Biovail’s filings with the SEC and, in Biovail’s case, the Canadian Securities Administrators (“CSA”), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.
Non-GAAP Information
To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a more meaningful, consistent comparison of the company’s core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. A reconciliation of GAAP to non-GAAP measures can be found in the tables below. The company has provided guidance with respect to adjusted non-GAAP (cash) earnings per share, which is a non-GAAP financial measure that represents earnings per share, excluding special charges and credits, restructuring and acquisition-related costs, amortization expense, ASC 470-20 (FSP APB 14-1) interest, gain on early extinguishment of debt and the non-GAAP tax effect of such charges. The company has not provided a reconciliation of this forward-looking non-GAAP financial measure due to the difficulty in forecasting and quantifying the exact amount of the items excluded from the non-GAAP financial measure that will be included in the comparable GAAP financial measure.
Note on Guidance
The guidance contained in this press release is only effective as of the date given, August 3, 2010, and will not be updated or confirmed until the Company publicly announces updated or affirmed guidance.
Financial Tables, including a reconciliation of GAAP to non-GAAP financial measures, follow.
Additional Information
In connection with the proposed merger, Biovail has filed with the SEC a Registration Statement on Form S-4 that includes a preliminary joint proxy statement of Valeant and Biovail that also constitutes a prospectus of Biovail. Valeant and Biovail will mail the definitive joint proxy statement/prospectus to their respective shareholders. INVESTORS ARE URGED TO READ THE PRELIMINARY JOINT PROXY STATEMENT/PROSPECTUS AND THE DEFINITIVE VERSION THEREOF WHEN IT BECOMES AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors may obtain the preliminary joint proxy statement/prospectus and the definitive version thereof when it becomes available, as well as other filings containing information about Valeant and Biovail, free of charge, at the website maintained by the SEC at www.sec.gov and, in Biovail’s case, on SEDAR at www.sedar.com. Investors may also obtain these documents, free of charge, from Valeant’s website (www.valeant.com) under the tab “Investor Relations” and then under the heading “SEC Filings,” or by directing a request to Valeant, One Enterprise, Aliso Viejo, California, 92656, Attention: Corporate Secretary. Investors may also obtain these documents, free of charge, from Biovail’s website (www.biovail.com) under the tab “Investor Relations” and then under the heading “Regulatory Filings” and then under the item “Current SEC Filings,” or by directing a request to Biovail, 7150 Mississauga Road, Mississauga, Ontario, Canada, L5N 8M5, Attention: Corporate Secretary.
The respective directors and executive officers of Valeant and Biovail and other persons may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Valeant’s directors and executive officers is available in its Annual Report on Form 10-K for the fiscal year ended December 31, 2009, which was filed with the SEC on February 24, 2010, and in its definitive proxy statement filed with the SEC by Valeant on March 25, 2010. Information regarding Biovail’s directors and executive officers is available in its Annual Report on Form 10-K for the fiscal year ended December 31, 2009, which was filed with the SEC on February 26, 2010, and in its definitive proxy statement filed with the SEC and CSA by Biovail on April 21, 2010. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the preliminary joint proxy statement/prospectus filed with the SEC. These documents can be obtained free of charge from the sources indicated above. Other information regarding the interests of the participants in the proxy solicitation will be included in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC and the CSA when they become available. This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
|
Valeant Pharmaceuticals International |
Table 1 |
|||||||||||
|
Statement of Income |
||||||||||||
|
For the Three and Six Months Ended June 30, 2010 and 2009 |
||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||
|
June 30, |
June 30, |
|||||||||||
|
(In thousands, except per share data) |
2010 |
2009 |
% Change |
2010 |
2009 |
% Change |
||||||
|
Product sales |
$ 219,458 |
$ 166,865 |
32% |
$ 423,965 |
$ 319,698 |
33% |
||||||
|
Service revenue |
4,396 |
5,606 |
-22% |
9,356 |
12,344 |
-24% |
||||||
|
Alliance revenue |
31,720 |
19,227 |
65% |
54,244 |
37,579 |
44% |
||||||
|
Total revenues |
255,574 |
191,698 |
33% |
487,565 |
369,621 |
32% |
||||||
|
Cost of goods sold |
60,638 |
42,750 |
42% |
114,841 |
82,447 |
39% |
||||||
|
Cost of services |
3,279 |
5,337 |
-39% |
6,445 |
9,663 |
-33% |
||||||
|
Selling, general and administrative ("SG&A") |
73,485 |
61,626 |
19% |
144,026 |
125,842 |
14% |
||||||
|
Research and development costs, net |
11,951 |
9,146 |
31% |
22,353 |
17,880 |
25% |
||||||
|
Special charges and credits |
1,012 |
1,974 |
1,550 |
1,974 |
||||||||
|
Restructuring and acquisition-related costs |
10,706 |
2,603 |
11,730 |
3,814 |
||||||||
|
Amortization expense |
22,335 |
17,105 |
31% |
41,665 |
34,109 |
22% |
||||||
|
183,406 |
140,541 |
30% |
342,610 |
275,729 |
24% |
|||||||
|
Income from operations |
72,168 |
51,157 |
144,955 |
93,892 |
||||||||
|
Interest expense, net |
(20,171) |
(7,825) |
(32,802) |
(14,004) |
||||||||
|
Gain on early extinguishment of debt |
- |
2,777 |
- |
7,376 |
||||||||
|
Other income (expense), net including translation and exchange |
(1,413) |
(647) |
(1,938) |
564 |
||||||||
|
Income from continuing operations before income taxes |
50,584 |
45,462 |
110,215 |
87,828 |
||||||||
|
Provision for income taxes |
18,348 |
12,427 |
42,378 |
23,996 |
||||||||
|
Income from continuing operations |
32,236 |
33,035 |
67,837 |
63,832 |
||||||||
|
Income (loss) from discontinued operations, net |
17 |
(175) |
432 |
223 |
||||||||
|
Net income |
$ 32,253 |
$ 32,860 |
$ 68,269 |
$ 64,055 |
||||||||
|
Earnings per share: |
||||||||||||
|
Basic: |
||||||||||||
|
Income from continuing operations |
$ 0.42 |
$ 0.40 |
$ 0.87 |
$ 0.77 |
||||||||
|
Discontinued operations |
- |
- |
0.01 |
- |
||||||||
|
Basic earnings per share |
$ 0.42 |
$ 0.40 |
$ 0.88 |
$ 0.77 |
||||||||
|
Shares used in per share computation |
77,136 |
82,794 |
77,797 |
82,733 |
||||||||
|
Diluted: |
||||||||||||
|
Income from continuing operations |
$ 0.39 |
$ 0.39 |
$ 0.82 |
$ 0.76 |
||||||||
|
Discontinued operations |
- |
- |
0.01 |
0.01 |
||||||||
|
Diluted earnings per share |
$ 0.39 |
$ 0.39 |
$ 0.83 |
$ 0.77 |
||||||||
|
Shares used in per share computation |
82,638 |
83,673 |
82,355 |
83,566 |
||||||||
|
Valeant Pharmaceuticals International |
Table 2 |
||||||||
|
Reconciliation of GAAP EPS to Adjusted Non-GAAP (Cash) EPS |
|||||||||
|
For the Three and Six Months Ended June 30, 2010 and 2009 |
|||||||||
|
Three Months Ended |
Six Months Ended |
||||||||
|
June 30, |
June 30, |
||||||||
|
(In thousands, except per share data) |
2010 |
2009 |
2010 |
2009 |
|||||
|
Income from continuing operations |
$ 32,236 |
$ 33,035 |
$ 67,837 |
$ 63,832 |
|||||
|
Non-GAAP adjustments (a)(b): |
|||||||||
|
Inventory step-up (c) |
2,500 |
- |
2,500 |
- |
|||||
|
Special charges and credits |
1,012 |
1,974 |
1,550 |
1,974 |
|||||
|
Restructuring and acquisition-related costs (d) |
10,706 |
2,603 |
11,730 |
3,814 |
|||||
|
Amortization expense |
22,335 |
17,105 |
41,665 |
34,109 |
|||||
|
36,553 |
21,682 |
57,445 |
39,897 |
||||||
|
ASC 470-20 (FSP APB 14-1) interest |
2,037 |
2,695 |
4,034 |
6,174 |
|||||
|
Gain on early extinguishment of debt |
- |
(2,778) |
- |
(7,376) |
|||||
|
Tax |
(13,755) |
(11,388) |
(19,432) |
(21,225) |
|||||
|
Total adjustments |
24,835 |
10,211 |
42,047 |
17,470 |
|||||
|
Adjusted income from continuing operations |
$ 57,071 |
$ 43,246 |
$ 109,884 |
$ 81,302 |
|||||
|
GAAP earnings per share - diluted |
$ 0.39 |
$ 0.39 |
$ 0.82 |
$ 0.76 |
|||||
|
Adjusted Non-GAAP (Cash) earnings per share - diluted |
$ 0.69 |
$ 0.52 |
$ 1.33 |
$ 0.97 |
|||||
|
Shares used in diluted per share calculation - GAAP earnings per share |
82,638 |
83,673 |
82,355 |
83,566 |
|||||
|
Shares used in diluted per share calculation - Adjusted Non-GAAP (Cash) earnings per share |
82,638 |
83,673 |
82,355 |
83,566 |
|||||
|
(a) To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures |
|||||||||
|
(b) This table includes Adjusted Non-GAAP (Cash) Earnings Per Share, which is a non-GAAP financial measure that represents earnings per share, excluding amortization |
|||||||||
|
(c) ASC 805, accounting for business combinations requires an inventory fair value step-up. The impact of the amortization of this step-up is included in cost of goods sold. |
|||||||||
|
(d) Restructuring and acquisition-related costs for the three and six months ended June 30, 2010 include $4.8 million of expenses related to the merger with Biovail, $3.2 |
|||||||||
|
Valeant Pharmaceuticals International |
Table 3 |
|||||||||||||||||||
|
Statement of Revenue - by Segment |
||||||||||||||||||||
|
For the Three and Six Months Ended June 30, 2010 and 2009 |
||||||||||||||||||||
|
(In thousands) |
||||||||||||||||||||
|
Three Months Ended |
||||||||||||||||||||
|
June 30, |
||||||||||||||||||||
|
Revenue (a)(b) |
2010 |
2009 |
% |
2010 |
2010 |
% |
2010 |
2010 |
Q2 2010 |
|||||||||||
|
Specialty pharmaceuticals |
||||||||||||||||||||
|
U.S. |
||||||||||||||||||||
|
Dermatology |
$ 35,694 |
$ 29,486 |
21% |
$ (17) |
$ 35,677 |
21% |
$ (3,668) |
$ 32,009 |
9% |
|||||||||||
|
Neurology & Other |
54,727 |
41,842 |
31% |
- |
54,727 |
31% |
(7,822) |
46,905 |
12% |
|||||||||||
|
Total U.S. |
90,421 |
71,328 |
27% |
(17) |
90,404 |
27% |
(11,490) |
78,914 |
11% |
|||||||||||
|
Canada |
22,817 |
15,831 |
44% |
(2,674) |
20,143 |
27% |
(3,543) |
16,600 |
5% |
|||||||||||
|
Australia |
13,663 |
9,475 |
44% |
(1,936) |
11,727 |
24% |
(3,936) |
7,791 |
-18% |
|||||||||||
|
Specialty pharmaceuticals product sales |
126,901 |
96,634 |
31% |
(4,627) |
122,274 |
27% |
(18,969) |
103,305 |
7% |
|||||||||||
|
Services and alliance revenue |
30,143 |
12,196 |
NM |
13 |
30,156 |
NM |
- |
30,156 |
NM |
|||||||||||
|
Total specialty pharmaceuticals revenue |
157,044 |
108,830 |
44% |
(4,614) |
152,430 |
40% |
(18,969) |
133,461 |
23% |
|||||||||||
|
Branded generics - Latin America product sales |
51,772 |
36,199 |
43% |
(3,464) |
48,308 |
33% |
(11,837) |
36,471 |
1% |
|||||||||||
|
Branded generics - Europe product sales |
40,785 |
34,032 |
20% |
(979) |
39,806 |
17% |
(2,713) |
37,093 |
9% |
|||||||||||
|
Alliances (ribavirin royalties only) |
5,973 |
12,637 |
-53% |
- |
5,973 |
-53% |
- |
5,973 |
NM |
|||||||||||
|
Total revenue |
$ 255,574 |
$ 191,698 |
33% |
$ (9,057) |
$ 246,517 |
29% |
$ (33,519) |
$ 212,998 |
11% |
|||||||||||
|
Total product sales included above |
$ 219,458 |
$ 166,865 |
32% |
$ (9,070) |
$ 210,388 |
26% |
$ (33,519) |
$ 176,869 |
6% |
|||||||||||
|
Six Months Ended |
||||||||||||||||||||
|
June 30, |
||||||||||||||||||||
|
Revenue (a)(b) |
2010 |
2009 |
% |
2010 |
2010 |
% |
2010 |
2010 |
Jun Ytd 2010 |
|||||||||||
|
Specialty pharmaceuticals |
||||||||||||||||||||
|
U.S. |
||||||||||||||||||||
|
Dermatology |
$ 70,219 |
$ 60,454 |
16% |
$ (37) |
$ 70,182 |
16% |
$ (4,634) |
$ 65,548 |
8% |
|||||||||||
|
Neurology & Other |
106,480 |
77,853 |
37% |
- |
106,480 |
37% |
(7,822) |
98,658 |
27% |
|||||||||||
|
Total U.S. |
176,699 |
138,307 |
28% |
(37) |
176,662 |
28% |
(12,456) |
164,206 |
19% |
|||||||||||
|
Canada |
44,640 |
30,319 |
47% |
(6,219) |
38,421 |
27% |
(5,572) |
32,849 |
8% |
|||||||||||
|
Australia |
26,304 |
14,321 |
84% |
(5,282) |
21,022 |
47% |
(8,408) |
12,614 |
-12% |
|||||||||||
|
Specialty pharmaceuticals product sales |
247,643 |
182,947 |
35% |
(11,538) |
236,105 |
29% |
(26,436) |
209,669 |
15% |
|||||||||||
|
Services and alliance revenue |
52,666 |
24,101 |
NM |
(113) |
52,553 |
NM |
- |
52,553 |
NM |
|||||||||||
|
Total specialty pharmaceuticals revenue |
300,309 |
207,048 |
45% |
(11,651) |
288,658 |
39% |
(26,436) |
262,222 |
27% |
|||||||||||
|
Branded generics - Latin America |
93,829 |
67,381 |
39% |
(9,037) |
84,792 |
26% |
(15,976) |
68,816 |
2% |
|||||||||||
|
Branded generics - Europe |
82,493 |
69,370 |
19% |
(7,909) |
74,584 |
8% |
(4,983) |
69,601 |
0% |
|||||||||||
|
Alliances (ribavirin royalties only) |
10,934 |
25,822 |
-58% |
- |
10,934 |
-58% |
- |
10,934 |
NM |
|||||||||||
|
Total revenue |
$ 487,565 |
$ 369,621 |
32% |
$ (28,597) |
$ 458,968 |
24% |
$ (47,395) |
$ 411,573 |
11% |
|||||||||||
|
Total product sales included above |
$ 423,965 |
$ 319,698 |
33% |
$ (28,484) |
$ 395,481 |
24% |
$ (47,395) |
$ 348,086 |
9% |
|||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||
|
June 30, |
June 30, |
|||||||||||||
|
2010 |
2009 |
2010 |
2009 |
|||||||||||
|
Alliance Revenue |
Segment |
|||||||||||||
|
Ribavirin royalty |
Alliances |
$ 5,973 |
$ 12,637 |
$ 10,934 |
$ 25,822 |
|||||||||
|
1% clindamycin and 5% benzoyl peroxide (IDP 111) profit share |
Specialty |
11,232 |
- |
20,530 |
- |
|||||||||
|
Other royalties |
Specialty |
4,160 |
3,790 |
7,585 |
5,639 |
|||||||||
|
License payments |
Specialty |
765 |
- |
1,466 |
- |
|||||||||
|
GSK collaboration |
Specialty |
9,590 |
2,800 |
13,729 |
6,118 |
|||||||||
|
Total alliance revenue |
$ 31,720 |
$ 19,227 |
$ 54,244 |
$ 37,579 |
||||||||||
|
(a) Note: Currency effect for constant currency sales is determined by comparing 2010 reported amounts adjusted to exclude currency impact, calculated using 2009 monthly |
||||||||||||||
|
(b) See footnote (a) to Table 2. |
||||||||||||||
|
Valeant Pharmaceuticals International |
Table 4 |
|||||||||||||||||||
|
Statement of Cost of Goods Sold and Non-GAAP Operating Income - by Segment |
||||||||||||||||||||
|
For the Three and Six Months Ended June 30, 2010 and 2009 |
||||||||||||||||||||
|
(In thousands) |
||||||||||||||||||||
|
4.1 |
Cost of goods sold |
|||||||||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||||||||
|
June 30, |
June 30, |
|||||||||||||||||||
|
2010 |
% of |
2009 |
% of |
2010 |
% of |
2009 |
% of |
|||||||||||||
|
Specialty pharmaceuticals |
$ 22,120 |
17% |
$ 18,181 |
19% |
$ 45,123 |
18% |
$ 33,544 |
18% |
||||||||||||
|
Branded generics - Latin America |
20,656 |
40% |
9,598 |
27% |
33,621 |
36% |
17,496 |
26% |
||||||||||||
|
Branded generics - Europe |
17,638 |
43% |
14,984 |
44% |
35,770 |
43% |
31,401 |
45% |
||||||||||||
|
Corporate |
224 |
(13) |
327 |
6 |
||||||||||||||||
|
$ 60,638 |
28% |
$ 42,750 |
26% |
$ 114,841 |
27% |
$ 82,447 |
26% |
|||||||||||||
|
4.2 |
Non-GAAP operating income excluding currency impact (a)(b) |
|||||||||||||||
|
Three Months Ended |
||||||||||||||||
|
June 30, |
||||||||||||||||
|
2010 |
% of |
2010 |
2010 |
% of |
2009 |
% of |
||||||||||
|
Specialty pharmaceuticals |
$ 88,853 |
57% |
$ (1,516) |
$ 87,337 |
56% |
$ 49,842 |
46% |
|||||||||
|
Branded generics - Latin America |
15,097 |
29% |
(844) |
14,253 |
28% |
14,628 |
40% |
|||||||||
|
Branded generics - Europe |
10,830 |
27% |
(342) |
10,488 |
26% |
8,196 |
24% |
|||||||||
|
114,780 |
46% |
(2,702) |
112,078 |
45% |
72,666 |
41% |
||||||||||
|
Alliances & Corporate |
(6,059) |
- |
(6,059) |
174 |
||||||||||||
|
$ 108,721 |
43% |
$ (2,702) |
$ 106,019 |
41% |
$ 72,840 |
38% |
||||||||||
|
Six Months Ended |
||||||||||||||||
|
June 30, |
||||||||||||||||
|
2010 |
% of |
2010 |
2010 |
% of |
2009 |
% of |
||||||||||
|
Specialty pharmaceuticals |
$ 167,520 |
56% |
$ (3,574) |
$ 163,946 |
55% |
$ 94,083 |
45% |
|||||||||
|
Branded generics - Latin America |
29,623 |
32% |
(2,909) |
26,714 |
28% |
27,615 |
41% |
|||||||||
|
Branded generics - Europe |
22,530 |
27% |
(2,481) |
20,049 |
24% |
17,294 |
25% |
|||||||||
|
219,673 |
46% |
(8,964) |
210,709 |
44% |
138,992 |
40% |
||||||||||
|
Alliances & Corporate |
(17,273) |
- |
(17,273) |
(5,203) |
||||||||||||
|
$ 202,400 |
42% |
$ (8,964) |
$ 193,436 |
40% |
$ 133,789 |
36% |
||||||||||
|
(a) See footnote (a) to Table 2 |
||||||||||||||||
|
(b) Non-GAAP operating income of $108.7 million and $202.4 million for the three and six months ended June 30, 2010 excludes the following GAAP items from GAAP operating income of $72.2 million and $145.0 million: amortization of inventory step-up of $2.5 million and $2.5 million, special charges and credits of $1.0 million and $1.5 million, restructuring and acquisition-related costs of $10.7 million and $11.7 million and amortization expense of $22.3 million and $41.7 million respectively. Non-GAAP operating income of $72.8 million and $133.8 million for the three and six months ended June 30, 2009 excludes the following GAAP items from GAAP operating income of $51.2 million and $93.9 million: special charges and credits of $2.0 million and $2.0 million, restructuring and acquisition-related costs of $2.6 million and $3.8 million and amortization expense of $17.0 million and $34.1 million respectively. |
||||||||||||||||
|
Valeant Pharmaceuticals International |
Table 5 |
||||||||
|
Consolidated Balance Sheet and Other Data |
|||||||||
|
(In thousands) |
|||||||||
|
As of |
As of |
||||||||
|
June 30, |
December 31, |
||||||||
|
5.1 |
Cash |
2010 |
2009 |
||||||
|
Cash and cash equivalents |
$ 75,383 |
$ 68,080 |
|||||||
|
Marketable securities |
- |
13,785 |
|||||||
|
Total cash and marketable securities |
$ 75,383 |
$ 81,865 |
|||||||
|
5.2 |
Summary of Cash Flow Statement |
Three Months Ended |
Six Months Ended |
||||||
|
June 30, |
June 30, |
||||||||
|
2010 |
2009 |
2010 |
2009 |
||||||
|
Cash flow provided by (used in): |
|||||||||
|
Operating activities, continuing operations (GAAP) |
$ 59,881 |
$ 44,461 |
$ 128,071 |
$ 82,283 |
|||||
|
Effect of ASC 470-20 (FSP APB 14-1) (a)(b) |
- |
9,710 |
- |
22,987 |
|||||
|
Acquisition transaction fees (a)(b) |
1,814 |
866 |
2,774 |
866 |
|||||
|
Operating activities, continuing operations (Non-GAAP) (a)(b) |
61,695 |
55,037 |
130,845 |
106,136 |
|||||
|
Operating activities, discontinued operations |
30 |
(285) |
(11) |
(2,434) |
|||||
|
Investing activities (GAAP) (c) |
(448,972) |
(151,028) |
(461,200) |
(187,594) |
|||||
|
Acquisition transaction fees (a)(b) |
(1,814) |
(866) |
(2,774) |
(866) |
|||||
|
Investing activities (Non-GAAP) (a)(b)(c) |
(450,786) |
(151,894) |
(463,974) |
(188,460) |
|||||
|
Financing activities (GAAP) |
319,108 |
305,512 |
341,155 |
261,775 |
|||||
|
Effect of ASC 470-20 (FSP APB 14-1) (a)(b) |
- |
(9,710) |
- |
(22,987) |
|||||
|
Financing activities (Non-GAAP) (a)(b) |
319,108 |
295,802 |
341,155 |
238,788 |
|||||
|
Effect of exchange rate changes on cash and cash equivalents |
(1,967) |
7,051 |
(712) |
(7,992) |
|||||
|
Net increase (decrease) in cash and cash equivalents (c) |
(71,920) |
205,711 |
7,303 |
146,038 |
|||||
|
Net decrease in marketable securities |
(7,979) |
101,429 |
(13,785) |
88,166 |
|||||
|
Net increase (decrease) in cash and marketable securities (c) |
$ (79,899) |
$ 307,140 |
$ (6,482) |
$ 234,204 |
|||||
|
(a) See footnote (a) to Table 2. |
|||||||||
|
(b) Cash flow for the three and six months ended June 30, 2010 includes $1.3 million and $1.5 million for acquisition fees related to the |
|||||||||
|
(c) Includes results from discontinued operations. |
|||||||||
|
Three Months Ended |
||||||||
|
5.3 |
GSK Collaboration - Retigabine |
June 30, 2010 |
||||||
|
Valeant SG&A |
$ 54 |
|||||||
|
Valeant R&D |
3,673 |
|||||||
|
3,727 |
||||||||
|
GSK incurred cost |
9,009 |
|||||||
|
$ 12,736 |
||||||||
|
Equalization (difference between individual partner costs and 50% of total) |
$ (2,641) |
|||||||
|
Three Months Ended June 30, 2010 |
|||||||||
|
Balance sheet |
Alliance |
SG&A |
R&D |
||||||
|
Accounting impact |
|||||||||
|
Upfront payment from GSK |
$ 125,000 |
$ - |
$ - |
$ - |
|||||
|
Release from upfront payment in prior quarters |
(67,835) |
- |
- |
- |
|||||
|
Incurred cost in current quarter |
- |
- |
54 |
3,673 |
|||||
|
Release from upfront payment in current quarter |
(15,958) |
(9,590) |
(661) |
(5,707) |
|||||
|
Remaining upfront payment from GSK |
$ 41,207 |
- |
- |
- |
|||||
|
Equalization payable to GSK |
$ (2,641) |
- |
607 |
2,034 |
|||||
|
$ (9,590) |
$ - |
$ - |
|||||||
(Logo: http://photos.prnewswire.com/prnh/20081125/VALEANTLOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)
SOURCE Valeant Pharmaceuticals International